The US shift toward steep tariffs will likely make drugs more expensive and limit access for patients, according to one of ...

Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first ...

Sandoz is one of the largest biosimilars players in the world and we believe it is well-positioned to benefit from the fast pace of growth the market is expected to enjoy over the next decade. Sandoz ...

Melbourne: Avecho Biotechnology Limited has announced it has signed an exclusive ten-year development and licensing agreement ...

Novo Nordisk plans to offer its Wegovy weight loss drug at a reduced cost of $499 per month for cash-paying customers in the ...

Along with the $350 million upfront fee Sandoz is also pledging $150 million tied to sales performance in the deal, which excludes some rights to the drug in some markets including the US ...

This leaflet answers some common questions about Cyclosporin Sandoz. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

Based on RBA exchange rate of 1 USD = 1.61 AUD as at 28 th February 2025. [2] Fresh Leaf Analytics, Australian Medicinal Cannabis Market, H1 2021.

Generic and biosimilar drug producer Sandoz has agreed a $265 million settlement that aims to put allegations of price-fixing brought in a Pennsylvania lawsuit behind it. The agreement – which ...

Biosimilars drove this increase with a 30% CER rise, while generics grew 2% CER. Core EBITDA for the second half was $40 million above consensus, with a full-year margin of 20.1%, exceeding the 19.7% ...

" data-display-label="0" data-show-count="1" data-bookmark-label="Save" data-bookmarked-label="Saved" data-loggedin="0" ...